(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Telescope in Chile captures stunning new picture of a cosmic butterfly - 2UN panel says Israel operating 'de facto policy of torture'
- 3The Most Encouraging New companies to Look Out For
- 4Reports: Germany plans expansion of foreign intelligence powers
- 5How is 'A Knight of the Seven Kingdoms' connected to 'Game of Thrones'?
- Pick Your Favored kind of sandwich
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- Improving as a Pioneer: Examples from My Vocation
- Scientists discover black hole flare with the light of 10 trillion suns
- Creativity Revealed: A Survey of \Making Shocking Looks\ Cosmetics Item
- Cannabis reclassification could 'open the floodgates' for research, scientists say
- 6 Exercises to Anticipate in 2024
- First SpaceX booster for upgraded Starship fails during test in Texas
- The risk of falling space junk hitting airplanes is on the rise, experts warn
